Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand

Massively parallel sequencing and targeted exomes in familial kidney disease can diagnose underlying genetic disorders

(2017) Andrew J. Mallett et al.   KIDNEY INTERNATIONAL

Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference

(2017) Timothy H.J. Goodship et al.   KIDNEY INTERNATIONAL

Haemolytic uraemic syndrome

(2017) Fadi Fakhouri et al.   LANCET

Thrombotic microangiopathy caused by methionine synthase deficiency: diagnosis and treatment pitfalls

(2017) Maria Helena Vaisbich et al.   PEDIATRIC NEPHROLOGY

Midterm Outcomes of 12 Renal Transplant Recipients Treated With Eculizumab to Prevent Atypical Hemolytic Syndrome Recurrence

(2017) Charlène Levi et al.   TRANSPLANTATION

Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial

(2016) Fadi Fakhouri et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

The long-term outcomes of atypical haemolytic uraemic syndrome: a national surveillance study

(2016) Anne M Durkan et al.   ARCHIVES OF DISEASE IN CHILDHOOD

Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura

(2016) E. E. Page et al.   BLOOD

How we manage thrombotic microangiopathies in pregnancy

(2016) Mari R. Thomas et al.   BRITISH JOURNAL OF HAEMATOLOGY

Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura

(2016) Christopher J. Patriquin et al.   BRITISH JOURNAL OF HAEMATOLOGY

Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation

(2016) Fadi Fakhouri et al.   Clinical Journal of the American Society of Nephrology

Diagnosis and management of thrombotic thrombocytopenic purpura (TTP) in Australia: findings from the first 5 years of the Australian TTP/thrombotic microangiopathy registry

(2016) P. Blombery et al.   INTERNAL MEDICINE JOURNAL

Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab

(2016) Arif Asif et al.   JOURNAL OF NEPHROLOGY

Thrombotic Microangiopathy in Inverted Formin 2 – Mediated Renal Disease

(2016) Rachel C. Challis et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies

(2016) E. H. Phillips et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome

(2016) Larry A. Greenbaum et al.   KIDNEY INTERNATIONAL

Thrombotic Microangiopathy Care Pathway: A Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group

(2016) Ronald S. Go et al.   MAYO CLINIC PROCEEDINGS

Anti-complement-factor H-associated glomerulopathies

(2016) Marie-Agnes Dragon Durey et al.   Nature Reviews Nephrology

Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura

(2016) Flora Peyvandi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome

(2016) Dineke Westra et al.   PEDIATRIC NEPHROLOGY

Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy

(2016) Eric Mariotte et al.   Lancet Haematology

Discontinuation of Eculizumab Treatment in Atypical Hemolytic Uremic Syndrome: An Update

(2015) Gianluigi Ardissino et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

The utility of ADAMTS13 in differentiating TTP from other acute thrombotic microangiopathies: results from the UK TTP Registry

(2015) Sevda Hassan et al.   BRITISH JOURNAL OF HAEMATOLOGY

Thrombotic thrombocytopenic purpura

(2015) Eric Mariotte et al.   Current Opinion in Critical Care

Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort

(2015) A. Mallett et al.   INTERNAL MEDICINE JOURNAL

High-Throughput Genetic Testing for Thrombotic Microangiopathies and C3 Glomerulopathies

(2015) F. Bu et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies

(2015) Christoph Licht et al.   KIDNEY INTERNATIONAL

Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria

(2015) Richard J. Kelly et al.   NEW ENGLAND JOURNAL OF MEDICINE

A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab

(2015) Gesa Schalk et al.   PEDIATRIC NEPHROLOGY

An international consensus approach to the management of atypical hemolytic uremic syndrome in children

(2015) Chantal Loirat et al.   PEDIATRIC NEPHROLOGY

Case Report: Benefits and Challenges of Long-term Eculizumab in Atypical Hemolytic Uremic Syndrome

(2015) N. Cullinan et al.   PEDIATRICS

A national specialized service in England for atypical haemolytic uraemic syndrome—the first year’s experience

(2015) N.S. Sheerin et al.   QJM-AN INTERNATIONAL JOURNAL OF MEDICINE

Platelet transfusion and catheter insertion for plasma exchange in patients with thrombotic thrombocytopenic purpura and a low platelet count

(2015) Etienne Riviere et al.   TRANSFUSION

The global aHUS registry: methodology and initial patient characteristics

(2015) Christoph Licht et al.   BMC Nephrology

Discontinuation of Eculizumab Maintenance Treatment for Atypical Hemolytic Uremic Syndrome: A Report of 10 Cases

(2014) Gianluigi Ardissino et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Drug-induced thrombotic microangiopathy: a systematic review of published reports

(2014) Z. L. Al-Nouri et al.   BLOOD

How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome

(2014) S. R. Cataland et al.   BLOOD

Genetic Variants in C5 and Poor Response to Eculizumab

(2014) Jun-ichi Nishimura et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adult-Onset Eculizumab-Resistant Hemolytic Uremic Syndrome Associated With Cobalamin C Deficiency

(2013) Emilie Cornec-Le Gall et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Complement Genes Strongly Predict Recurrence and Graft Outcome in Adult Renal Transplant Recipients with Atypical Hemolytic and Uremic Syndrome

(2013) M. Le Quintrec et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Genetics and Outcome of Atypical Hemolytic Uremic Syndrome: A Nationwide French Series Comparing Children and Adults

(2013) V. Fremeaux-Bacchi et al.   Clinical Journal of the American Society of Nephrology

Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research

(2013) Ravi Sarode et al.   JOURNAL OF CLINICAL APHERESIS

Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children

(2013) Aditi Sinha et al.   KIDNEY INTERNATIONAL

Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome

(2013) Mathieu Lemaire et al.   NATURE GENETICS

ADAMTS13 Antibody Depletion by Bortezomib in Thrombotic Thrombocytopenic Purpura

(2013) Jake Shortt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

(2013) C.M. Legendre et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trends in US Hospital Stays for Streptococcus pneumoniae–associated Hemolytic Uremic Syndrome

(2013) Angela F. Veesenmeyer et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

The use of ADAMTS13 activity, platelet count, and serum creatinine to differentiate acquired thrombotic thrombocytopenic purpura from other thrombotic microangiopathies

(2012) Spero R. Cataland et al.   BRITISH JOURNAL OF HAEMATOLOGY

Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies

(2012) Marie Scully et al.   BRITISH JOURNAL OF HAEMATOLOGY

Best supportive care and therapeutic plasma exchange with or without eculizumab in Shiga-toxin-producing E. coli O104:H4 induced haemolytic–uraemic syndrome: an analysis of the German STEC-HUS registry

(2012) Jan T. Kielstein et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Thrombotic microangiopathy and associated renal disorders

(2012) T. Barbour et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience

(2012) François Beloncle et al.   TRANSFUSION

Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study

(2012) J. Menne et al.   BMJ-British Medical Journal

A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura

(2011) M. Scully et al.   BLOOD

Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies

(2011) B. PLAIMAUER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Complement factor H variants I890 and L1007 while commonly associated with atypical hemolytic uremic syndrome are polymorphisms with no functional significance

(2011) Agustín Tortajada et al.   KIDNEY INTERNATIONAL

Origins of theE. coliStrain Causing an Outbreak of Hemolytic–Uremic Syndrome in Germany

(2011) David A. Rasko et al.   NEW ENGLAND JOURNAL OF MEDICINE

How I treat patients with thrombotic thrombocytopenic purpura: 2010

(2010) J. N. George   BLOOD

Relative Role of Genetic Complement Abnormalities in Sporadic and Familial aHUS and Their Impact on Clinical Phenotype

(2010) M. Noris et al.   Clinical Journal of the American Society of Nephrology

Clinical Features of Anti-Factor H Autoantibody-Associated Hemolytic Uremic Syndrome

(2010) M.-A. Dragon-Durey et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Predictive Features of Severe Acquired ADAMTS13 Deficiency in Idiopathic Thrombotic Microangiopathies: The French TMA Reference Center Experience

(2010) Paul Coppo et al.   PLoS One

Efficacy and Safety Profile of Solvent/Detergent Plasma in the Treatment of Acute Thrombotic Thrombocytopenic Purpura: A Single-Center Experience

(2010) Elvira Edel et al.   TRANSFUSION MEDICINE AND HEMOTHERAPY

Survival and relapse in patients with thrombotic thrombocytopenic purpura

(2009) J. A. K. Hovinga et al.   BLOOD

ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission

(2008) F. Peyvandi et al.   HAEMATOLOGICA